Shots: Post EMA’s ODD, A4250 has received FDA’s ODD following its P-III study assessing A4250 in patients with Alagille syndrome, biliary atresia and primary biliary cholangitis (PBC) FDA has granted […]readmore
Tags : Biliary Atresia
Shots: The designation is based on P-III clinical trial assessing A4250 in patients with progressive familial intrahepatic cholestasis (PFIC) Albireo to get 10 years of market exclusivity with additional two years on completion of pediatric […]readmore